Geneva, Switzerland, May 31, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological.
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio.
Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 5,500 shares, a drop of 62.6% from the April 30th total of 14,700 shares. Based on an average trading volume of 19,800 shares, the days-to-cover ratio […]
Addex to Present at Bio€quity Europe 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.